AR046445A1 - Derivados de piridazin-3(2h)-ona - Google Patents
Derivados de piridazin-3(2h)-onaInfo
- Publication number
- AR046445A1 AR046445A1 ARP040104120A ARP040104120A AR046445A1 AR 046445 A1 AR046445 A1 AR 046445A1 AR P040104120 A ARP040104120 A AR P040104120A AR P040104120 A ARP040104120 A AR P040104120A AR 046445 A1 AR046445 A1 AR 046445A1
- Authority
- AR
- Argentina
- Prior art keywords
- mono
- amino
- alkoxy
- hydroxy
- group
- Prior art date
Links
- 125000003545 alkoxy group Chemical group 0.000 abstract 21
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 21
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 20
- 125000005843 halogen group Chemical group 0.000 abstract 20
- 125000001424 substituent group Chemical group 0.000 abstract 20
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 18
- 125000004414 alkyl thio group Chemical group 0.000 abstract 16
- 125000000217 alkyl group Chemical group 0.000 abstract 14
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 14
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 abstract 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 14
- 125000005530 alkylenedioxy group Chemical group 0.000 abstract 13
- 125000002252 acyl group Chemical group 0.000 abstract 12
- 125000004442 acylamino group Chemical group 0.000 abstract 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 12
- 125000005110 aryl thio group Chemical group 0.000 abstract 11
- 125000004104 aryloxy group Chemical group 0.000 abstract 11
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 10
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 abstract 9
- 125000004043 oxo group Chemical group O=* 0.000 abstract 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 7
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 6
- 125000004423 acyloxy group Chemical group 0.000 abstract 5
- 125000003342 alkenyl group Chemical group 0.000 abstract 5
- -1 monoalkylamino Chemical group 0.000 abstract 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 4
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000005842 heteroatom Chemical group 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 239000001301 oxygen Chemical group 0.000 abstract 4
- 229910052717 sulfur Chemical group 0.000 abstract 4
- 239000011593 sulfur Chemical group 0.000 abstract 4
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 abstract 3
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 3
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 3
- 125000000304 alkynyl group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000005036 alkoxyphenyl group Chemical group 0.000 abstract 2
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 abstract 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 2
- 125000003277 amino group Chemical group 0.000 abstract 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 2
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 abstract 2
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 2
- 125000005117 dialkylcarbamoyl group Chemical group 0.000 abstract 2
- 125000005059 halophenyl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000002950 monocyclic group Chemical group 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 abstract 1
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 125000000676 alkoxyimino group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/22—Nitrogen and oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Manufacturing & Machinery (AREA)
- Pulmonology (AREA)
- Ceramic Engineering (AREA)
- Structural Engineering (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Procedimientos para su preparación y composiciones farmacéuticas que los contienen. Estos compuestos son inhibidores de potentes y selectivos de la fosfodiesterasa 4 (PDE4) y por ello son útiles en el tratamiento, prevención o supresión de estados patológicos, enfermedades y trastornos que se conocen por ser susceptibles de mejorar mediante la inhibición de la PDE4. Reivindicación 1: Un derivado de piridazinona de fórmula (1), en el que, R1 representa: un átomo de hidrógeno; un grupo seleccionado de acilo, alcoxicarbonilo, carbamoilo, monoalquilcarbamoilo o dialquilcarbamoilo; un grupo alquilo, alquenilo o alquinilo, que está sustituido opcionalmente por uno o más sustituyentes seleccionados de átomos de halógenos y grupos hidroxi, alcoxi, ariloxi, alquiltio, ariltio, oxo, amino, mono- o di-alquilamino, acilamino, hidroxicarbonilo, alcoxicarbonilo, carbamoilo o mono- o di-alquilcarbamoilo; un grupo arilo o heteroarilo que está sustituido opcionalmente por uno o más sustituyentes seleccionados de átomos de halógenos y grupos hidroxi, hidroxialquilo, hidroxicarbonilo, alcoxi, alquilendioxi, alcoxicarbonilo, ariloxi, acilo, aciloxi, alquiltio, ariltio, amino, nitro, ciano, mono- o di-alquilamino, acilamino, carbamoilo o mono- o di-alquilcarbamoilo, difluorometilo, trifluorometilo, difluorometoxi o trifluorometoxi; un grupo heterocíclico saturado o insaturado que está sustituido opcionalmente por uno o más sustituyentes seleccionados de átomos de halógenos y grupos hidroxi, hidroxialquilo, hidroxicarbonilo, alcoxi, alquilendioxi, alcoxicarbonilo, ariloxi, acilo, aciloxi, alquiltio, ariltio, oxo, amino, nitro, ciano, mono- o di-alquilamino, acilamino, carbamoilo o mono- o di-alquilcarbamoilo, difluorometilo, trifluorometilo, difluorometoxi o trifluorometoxi; un grupo de fórmula: -(CH2)n-R6, donde n es un número entero de 0 a 4 y R6 representa: un grupo cicloalquilo o cicloalquenilo; un grupo arilo, que está sustituido opcionalmente por uno o más sustituyentes seleccionados de átomos de halógenos y grupos alquilo, hidroxi, alcoxi, alquilendioxi, alquiltio, amino, mono- o di-alquilamino, nitro, acilo, hidroxicarbonilo, alcoxicarbonilo, carbamoilo, mono- o di-alquilcarbamoilo, ciano, trifluorometilo, difluorometoxi o trifluorometoxi; o un anillo de 3 a 7 miembros que comprende de 1 a 4 heteroátomos seleccionados de nitrógeno, oxígeno, y azufre, cuyo anillo está sustituido opcionalmente por uno o más sustituyentes seleccionados de átomos de halógenos y grupos alquilo, hidroxi, alcoxi, alquilendioxi, amino, mono- o di-alquilamino, nitro, ciano o trifluorometilo; R2 representa: un átomo de hidrógeno; un grupo seleccionado de acilo, alcoxicarbonilo, carbamoilo, monoalquilcarbamoilo o dialquilcarbamoilo; un grupo alquilo, alquenilo o alquinilo, que está sustituido opcionalmente por uno o más sustituyentes seleccionados de átomos de halógenos y grupos hidroxi, alcoxi, hidroxicarbonilo, alcoxicarbonilo, ariloxi, alquiltio, ariltio, oxo, amino, mono- o di-alquilamino, acilamino, carbamoilo o mono- o di-alquilcarbamoilo; un grupo arilo o heteroarilo que está sustituido opcionalmente por uno o más sustituyentes seleccionados de átomos de halógenos y grupos hidroxi, hidroxialquilo, hidroxicarbonilo, alcoxi, alquilendioxi, alcoxicarbonilo, ariloxi, acilo, aciloxi, alquiltio, ariltio, amino, nitro, ciano, mono- o di-alquilamino, acilamino, carbamoilo o mono- o di-alquilcarbamoilo, difluorometilo, trifluorometilo, difluorometoxi o trifluorometoxi; un grupo heterocíclico saturado o insaturado que está sustituido opcionalmente por uno o más sustituyentes seleccionados de átomos de halógenos y grupos hidroxi, hidroxialquilo, hidroxicarbonilo, alcoxi, alquilendioxi, alcoxicarbonilo, ariloxi, acilo, aciloxi, alquiltio, ariltio, oxo, amino, nitro, ciano, mono- o di-alquilamino, acilamino, carbamoilo o mono- o di-alquilcarbamoilo, difluorometilo, trifluorometilo, difluorometoxi o trifluorometoxi; un grupo de fórmula: -(CH2)n-R6, donde n es un número entero de 0 a 4 y R6 representa: un grupo cicloalquilo o cicloalquenilo; un grupo arilo, que está sustituido opcionalmente por uno o más sustituyentes seleccionados de átomos de halógenos y grupos alquilo, hidroxi, alcoxi, alquilendioxi, alquiltio, amino, mono- o di-alquilamino, nitro, acilo, hidroxicarbonilo, alcoxicarbonilo, carbamoilo, mono- o di-alquilcarbamoilo, ciano, trifluorometilo, difluorometoxi o trifluorometoxi; o un anillo de 3 a 7 miembros que comprende de 1 a 4 heteroátomos seleccionados de nitrógeno, oxígeno, y azufre, cuyo anillo está sustituido opcionalmente por uno o más sustituyentes seleccionados de átomos de halógenos y grupos alquilo, hidroxi, alcoxi, alquilendioxi, amino, mono- o di-alquilamino, nitro, ciano o trifluorometilo; R3 representa un grupo arilo o heteroarilo monocíclico o policíclico, que está sustituido opcionalmente por uno o más sustituyentes seleccionados de: átomos de halógeno; un grupo alquilo y alquenilo, que están sustituidos opcionalmente por uno o más sustituyentes seleccionados de átomos de halógenos y grupos fenilo, hidroxi, alcoxi, ariloxi, alquiltio, ariltio, oxo, amino, mono- o di-alquilamino, acilamino, hidroxicarbonilo, alcoxicarbonilo, carbamoilo o mono- o di-alquilcarbamoilo; grupos fenilo, hidroxi, hidroxialquilo, alcoxi, cicloalcoxi, nitro, ciano, ariloxi, alquiltio, ariltio, alquilsulfinilo, alquilsulfonilo, alquilsulfamoilo, acilo, amino, mono- o di-alquilamino, acilamino, hidroxicarbonilo, alcoxicarbonilo, carbamoilo, mono- o di-alquilcarbamoilo, ureido, N'-alquilureido, N',N'-dialquilureido, alquilsulfamido, aminosulfonilo, mono- o di-alquilaminosulfonilo, difluorometoxi o trifluorometoxi; R4 representa: un átomo de hidrógeno; un grupo hidroxi, alcoxi, amino, monoalquilamino, dialquilamino o ciano; un grupo alquilo, alquenilo o alquinilo, que está sustituido opcionalmente por uno o más sustituyentes seleccionados de átomos de halógenos y grupos hidroxi, aciloxi, alcoxi, ariloxi, alquiltio, ariltio, amino, mono- o di-alquilamino, acilamino, hidroxicarbonilo, alcoxicarbonilo, alcoxiimino, carbamoilo y mono- o di-alquilcarbamoilo; o un grupo de fórmula: -(CH2)n-R6, donde n es un número entero de 0 a 4 y R6 representa un grupo cicloalquilo o cicloalquenilo; un grupo arilo, que está sustituido opcionalmente por uno o más sustituyentes seleccionados de átomos de halógenos y grupos alquilo, hidroxi, alcoxi, alquilendioxi, alquiltio, amino, mono- o di-alquilamino, nitro, acilo, hidroxicarbonilo, alcoxicarbonilo, carbamoilo, mono- o di-alquilcarbamoilo, ciano, trifluorometilo, difluorometoxi o trifluorometoxi; o un anillo de 3 a 7 miembros que comprende de 1 a 4 heteroátomos seleccionados de nitrógeno, oxígeno, y azufre, cuyo anillo está sustituido opcionalmente por uno o más sustituyentes seleccionados de átomos de halógenos y grupos alquilo, fenilo, alcoxifenilo, halofenilo, piridilo, alcoxicarbonilo, hidroxi, alcoxi, alquilendioxi, amino, mono- o di-alquilamino, nitro, ciano o trifluorometilo; R5 representa un grupo -COOR7 o un grupo arilo o heteroarilo monocíclico o policíclico, que está sustituido opcionalmente por uno o más sustituyentes seleccionados de: átomos de halógenos; un grupo alquilo y alquenilo, que están sustituidos opcionalmente por uno o más sustituyentes seleccionados de átomos de halógenos y grupos fenilo, hidroxi, hidroxialquilo, alcoxi, ariloxi, alquiltio, ariltio, oxo, amino, mono- o di-alquilamino, acilamino, hidroxicarbonilo, alcoxicarbonilo, carbamoilo o mono- o di-alquilcarbamoilo; y grupos fenilo, hidroxi, alquilendioxi, alcoxi, cicloalcoxi, alquiltio, alquilsulfinilo, alquilsulfonilo, alquilsulfamoilo, amino, mono- o di-alquilamino, acilamino, nitro, acilo, hidroxicarbonilo, alcoxicarbonilo, carbamoilo, mono- o di-alquilcarbamoilo, ureido, N'-alquilureido, N',N'-dialquilureido, alquilsulfamido, aminosulfonilo, mono- o di-alquilaminosulfonilo, ciano, difluorometoxi o trifluorometoxi; en el que R7 representa un alquilo que está sustituido opcionalmente por uno o más sustituyentes seleccionados de átomos de halógenos y grupos hidroxi, alcoxi, ariloxi, alquiltio, ariltio, oxo, amino, amino, mono- o di-alquilamino, acilamino, hidroxicarbonilo, alcoxicarbonilo, carbamoilo, mono- o di-alquilcarbamoilo o un grupo de fórmula: -(CH2)n-R6, donde n es un número entero de 0 a 4 y R6 representa un grupo cicloalquilo o cicloalquenilo; un grupo arilo, que está sustituido opcionalmente por uno o más sustituyentes seleccionados de átomos de halógenos y grupos alquilo, hidroxi, alcoxi, alquilendioxi, alquiltio, amino, mono- o di-alquilamino, nitro, acilo, hidroxicarbonilo, alcoxicarbonilo, carbamoilo, mono- o di-alquilcarbamoilo, ciano, trifluorometilo, difluorometoxi o trifluorometoxi; o un anillo de 3 a 7 miembros que comprende de 1 a 4 heteroátomos seleccionados de nitrógeno, oxígeno, y azufre, cuyo anillo está sustituido opcionalmente por uno o más sustituyentes seleccionados de átomos de halógenos y grupos alquilo, fenilo, alcoxifenilo, halofenilo, piridilo, alcoxicarbonilo, hidroxi, alcoxi, alquilendioxi, amino, mono- o di-alquilamino, nitro, ciano o trifluorometilo; y su sales o N-óxidos de los mismos; con la condición de que cuando R1 es metilo, R2 es H, y tanto R3 como R5 son fenilo, entonces R4 no es grupo 1-hidroxietilo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200302613A ES2232306B1 (es) | 2003-11-10 | 2003-11-10 | Nuevos derivados de piridazin-3(2h)-ona. |
Publications (1)
Publication Number | Publication Date |
---|---|
AR046445A1 true AR046445A1 (es) | 2005-12-07 |
Family
ID=34586123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040104120A AR046445A1 (es) | 2003-11-10 | 2004-11-09 | Derivados de piridazin-3(2h)-ona |
Country Status (20)
Country | Link |
---|---|
US (1) | US7511038B2 (es) |
EP (1) | EP1682519A1 (es) |
JP (1) | JP2007510689A (es) |
KR (1) | KR20070001907A (es) |
CN (1) | CN1878759A (es) |
AR (1) | AR046445A1 (es) |
AU (1) | AU2004291282A1 (es) |
BR (1) | BRPI0416212A (es) |
CA (1) | CA2545193A1 (es) |
CO (1) | CO5690558A2 (es) |
EC (1) | ECSP066541A (es) |
ES (1) | ES2232306B1 (es) |
IL (1) | IL175278A0 (es) |
NO (1) | NO20062726L (es) |
PE (1) | PE20050490A1 (es) |
RU (1) | RU2006120082A (es) |
TW (1) | TW200526593A (es) |
UA (1) | UA82420C2 (es) |
WO (1) | WO2005049581A1 (es) |
ZA (1) | ZA200602415B (es) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
US7214687B2 (en) | 1999-07-14 | 2007-05-08 | Almirall Ag | Quinuclidine derivatives and medicinal compositions containing the same |
ES2211344B1 (es) | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
EP1604988A1 (en) * | 2004-05-18 | 2005-12-14 | Sanofi-Aventis Deutschland GmbH | Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals |
ES2257152B1 (es) | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
ES2251866B1 (es) | 2004-06-18 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
ES2251867B1 (es) * | 2004-06-21 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
CA2584261A1 (en) * | 2004-10-13 | 2006-04-20 | Kyowa Hakko Kogyo Co., Ltd. | Pharmaceutical composition |
US20070287689A1 (en) * | 2004-10-13 | 2007-12-13 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic And/Or Preventive Agents For Chronic Skin Diseases |
ES2265276B1 (es) | 2005-05-20 | 2008-02-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
ES2298049B1 (es) | 2006-07-21 | 2009-10-20 | Laboratorios Almirall S.A. | Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano. |
ES2306595B1 (es) | 2007-02-09 | 2009-09-11 | Laboratorios Almirall S.A. | Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2. |
ES2320955B1 (es) | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
ES2320954B1 (es) * | 2007-03-02 | 2010-03-16 | Laboratorio Almirall S.A. | Nuevo procedimiento de preparacion de 3-metil-4-fenilisoxazolo (3,4-d)iridazin-7(6h)-ona. |
ES2320961B1 (es) | 2007-11-28 | 2010-03-17 | Laboratorios Almirall, S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2. |
ES2420846T3 (es) * | 2008-02-05 | 2013-08-27 | F. Hoffmann-La Roche Ag | Nuevas piridinonas y piridazinonas |
EP2096105A1 (en) * | 2008-02-28 | 2009-09-02 | Laboratorios Almirall, S.A. | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor |
EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
EP2108641A1 (en) | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
EP2113503A1 (en) | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
EP2196465A1 (en) * | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
UY32297A (es) | 2008-12-22 | 2010-05-31 | Almirall Sa | Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico |
EP2221297A1 (en) | 2009-02-18 | 2010-08-25 | Almirall, S.A. | 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases |
EP2221055A1 (en) | 2009-02-18 | 2010-08-25 | Almirall, S.A. | 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function |
EP2228368A1 (en) | 2009-03-12 | 2010-09-15 | Almirall, S.A. | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one |
EP2322176A1 (en) | 2009-11-11 | 2011-05-18 | Almirall, S.A. | New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives |
EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
EP2360158A1 (en) | 2010-02-18 | 2011-08-24 | Almirall, S.A. | Pyrazole derivatives as jak inhibitors |
EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
EP2394998A1 (en) * | 2010-05-31 | 2011-12-14 | Almirall, S.A. | 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors |
EP2397482A1 (en) | 2010-06-15 | 2011-12-21 | Almirall, S.A. | Heteroaryl imidazolone derivatives as jak inhibitors |
EP2441755A1 (en) | 2010-09-30 | 2012-04-18 | Almirall, S.A. | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors |
EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
EP2489663A1 (en) | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Compounds as syk kinase inhibitors |
EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
EP2518070A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
EP2518071A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Imidazopyridine derivatives as PI3K inhibitors |
EP2526945A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | New CRTH2 Antagonists |
EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
EP2548863A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists. |
EP2548876A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists |
EP2554544A1 (en) | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Pyridin-2(1h)-one derivatives as jak inhibitors |
EP2578570A1 (en) | 2011-10-07 | 2013-04-10 | Almirall, S.A. | Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis. |
EP2592077A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
EP2641900A1 (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
EP2647627A1 (en) | 2012-04-02 | 2013-10-09 | Almirall, S.A. | Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one. |
EP2666465A1 (en) | 2012-05-25 | 2013-11-27 | Almirall, S.A. | Novel dosage and formulation |
EP2668941A1 (en) | 2012-05-31 | 2013-12-04 | Almirall, S.A. | Novel dosage form and formulation of abediterol |
MX2014015156A (es) * | 2012-06-12 | 2015-08-06 | Abbvie Inc | Derivados de piridinona y piridazinona. |
WO2014060431A1 (en) | 2012-10-16 | 2014-04-24 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
EP2738172A1 (en) | 2012-11-28 | 2014-06-04 | Almirall, S.A. | New bicyclic compounds as crac channel modulators |
PT2931275T (pt) | 2012-12-17 | 2022-06-30 | Almirall Sa | Aclidínio para usar no aumento da atividade física na vida diária de um doente que sofre de doença pulmonar obstrutiva crónica |
ES2750523T3 (es) | 2012-12-18 | 2020-03-26 | Almirall Sa | Derivados de ciclohexil y quinuclidinil carbamato que tienen actividades de agonista beta2 adrenérgicos y antagonistas muscarínicos M3 |
UY35332A (es) | 2013-02-15 | 2014-11-28 | Almirall Sa | Derivados de pirrolotriazina como inhibidores de pi3k |
EP2848615A1 (en) | 2013-07-03 | 2015-03-18 | Almirall, S.A. | New pyrazole derivatives as CRAC channel modulators |
FR3027901B1 (fr) * | 2014-10-31 | 2018-03-16 | Universite De Reims Champagne Ardenne | Nouveaux procedes appartenant a la famille des pyridazinones. |
US11319318B2 (en) * | 2015-03-05 | 2022-05-03 | Boehringer Ingelheim International Gmbh | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 |
CN112533601A (zh) * | 2018-06-04 | 2021-03-19 | 俄亥俄州创新基金会 | Eaat2活化剂及其使用方法 |
CN109620829B (zh) * | 2018-12-29 | 2021-04-06 | 温州医科大学附属第一医院 | 一种治疗急性呼吸窘迫综合征的药物组合物及其制备方法 |
TW202321229A (zh) * | 2021-08-18 | 2023-06-01 | 美商富曼西公司 | 殺真菌的取代的雜環化合物 |
WO2023204124A1 (ja) * | 2022-04-20 | 2023-10-26 | 日本曹達株式会社 | ピリダジノン化合物並びに農園芸用殺菌剤、殺線虫剤、および医療用・動物用抗真菌剤 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2824873A (en) * | 1958-02-25 | Production of pyridazone derivatives | ||
US2786840A (en) * | 1957-03-26 | Aminopyridazone compounds and their | ||
DE579391C (de) * | 1932-02-07 | 1933-06-24 | Schering Kahlbaum Ag | Verfahren zur Darstellung von in 5-Stellung substituierten 1, 3-Dialkylpyridazonen |
GB656228A (en) * | 1948-12-30 | 1951-08-15 | Walter Norman Haworth | The manufacture of analgesics from pyridazone and pyridazine derivatives |
GB788393A (en) * | 1953-04-30 | 1958-01-02 | Ciba Ltd | Process for the manufacture of pyridazone compounds |
DE932489C (de) * | 1953-09-11 | 1955-09-01 | Hoffmann La Roche | Verfahren zur Herstellung von neuen Xanthinbasen und deren Salzen |
GB794870A (en) * | 1955-05-07 | 1958-05-14 | Basf Ag | A process for the production of 3-oxo-2,3-dihydropyridazine derivatives |
GB788502A (en) * | 1956-05-30 | 1958-01-02 | Chimie Atomistique | Pyridazine compounds and process of preparing the latter |
US2834780A (en) * | 1956-07-05 | 1958-05-13 | Dow Chemical Co | Phthalidyl piperazines |
US3014034A (en) * | 1959-01-22 | 1961-12-19 | Ciba Pharm Prod Inc | 1, 3-diaryl, 5-amino-pyridazinones |
GB889317A (en) * | 1959-01-22 | 1962-02-14 | Ciba Ltd | New phenyl-diazines and a process for their manufacture |
SU405344A1 (ru) | 1970-06-01 | 1975-08-25 | Всесоюзный научно-исследовательский химико-фармацевтический институт им. С.Орджоникидзе | Способ получени производных 3-замещенных 5-(2-оксифениламино)-пиридазона-6 |
JPS5312880A (en) * | 1976-07-21 | 1978-02-04 | Morishita Pharma | Pyridazinone derivatives |
TWI241295B (en) * | 1998-03-02 | 2005-10-11 | Kowa Co | Pyridazine derivative and medicine containing the same as effect component |
AU2001262332B2 (en) * | 2000-06-05 | 2006-05-25 | Altana Pharma Ag | Compounds effective as beta-2-adrenoreceptor agonists as well as PDE4-inhibitors |
SI1471054T1 (sl) * | 2002-01-11 | 2009-12-31 | Daiichi Sankyo Co Ltd | Amino alkoholni derivati ali derivati fosfoniäśne kisline in medicinski sestavki, ki vsebujejo le-te |
ES2211344B1 (es) * | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
WO2004085406A1 (en) * | 2003-03-24 | 2004-10-07 | F. Hoffmann-La Roche Ag | Benzyl-pyridazinons as reverse transcriptase inhibitors |
-
2003
- 2003-11-10 ES ES200302613A patent/ES2232306B1/es not_active Expired - Fee Related
-
2004
- 2004-08-11 UA UAA200606338A patent/UA82420C2/uk unknown
- 2004-11-08 KR KR1020067011454A patent/KR20070001907A/ko not_active Application Discontinuation
- 2004-11-08 US US10/578,594 patent/US7511038B2/en not_active Expired - Fee Related
- 2004-11-08 WO PCT/EP2004/012604 patent/WO2005049581A1/en active Application Filing
- 2004-11-08 CA CA002545193A patent/CA2545193A1/en not_active Abandoned
- 2004-11-08 JP JP2006538762A patent/JP2007510689A/ja active Pending
- 2004-11-08 RU RU2006120082/04A patent/RU2006120082A/ru not_active Application Discontinuation
- 2004-11-08 EP EP04797700A patent/EP1682519A1/en not_active Withdrawn
- 2004-11-08 BR BRPI0416212-9A patent/BRPI0416212A/pt not_active IP Right Cessation
- 2004-11-08 AU AU2004291282A patent/AU2004291282A1/en not_active Abandoned
- 2004-11-08 PE PE2004001087A patent/PE20050490A1/es not_active Application Discontinuation
- 2004-11-08 CN CNA2004800331136A patent/CN1878759A/zh active Pending
- 2004-11-09 AR ARP040104120A patent/AR046445A1/es unknown
- 2004-11-10 TW TW093134355A patent/TW200526593A/zh unknown
-
2006
- 2006-03-24 ZA ZA200602415A patent/ZA200602415B/en unknown
- 2006-04-27 IL IL175278A patent/IL175278A0/en unknown
- 2006-05-03 EC EC2006006541A patent/ECSP066541A/es unknown
- 2006-05-10 CO CO06044361A patent/CO5690558A2/es not_active Application Discontinuation
- 2006-06-12 NO NO20062726A patent/NO20062726L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20070001907A (ko) | 2007-01-04 |
IL175278A0 (en) | 2006-09-05 |
BRPI0416212A (pt) | 2007-01-02 |
ES2232306B1 (es) | 2006-08-01 |
US7511038B2 (en) | 2009-03-31 |
EP1682519A1 (en) | 2006-07-26 |
JP2007510689A (ja) | 2007-04-26 |
RU2006120082A (ru) | 2008-01-10 |
CO5690558A2 (es) | 2006-10-31 |
WO2005049581A1 (en) | 2005-06-02 |
CN1878759A (zh) | 2006-12-13 |
ZA200602415B (en) | 2007-11-28 |
UA82420C2 (en) | 2008-04-10 |
AU2004291282A1 (en) | 2005-06-02 |
WO2005049581A8 (en) | 2006-05-04 |
ECSP066541A (es) | 2006-12-20 |
ES2232306A1 (es) | 2005-05-16 |
NO20062726L (no) | 2006-06-12 |
CA2545193A1 (en) | 2005-06-02 |
PE20050490A1 (es) | 2005-08-24 |
US20070197536A1 (en) | 2007-08-23 |
TW200526593A (en) | 2005-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR046445A1 (es) | Derivados de piridazin-3(2h)-ona | |
AR042665A1 (es) | Derivados de piridazin -3 (2 h) - ona | |
AR040076A1 (es) | Derivados de piridazin-3(2h)-ona | |
AR051738A1 (es) | Derivados de piridazin-3(2h)-ona, composicin farmaceutica, y uso del compuesto para fabricar medicamentos | |
AR049402A1 (es) | Derivados de piridazin-3-(2h)-ona | |
PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
TW200611907A (en) | Fused heterocyclic compound | |
ES2601518T3 (es) | Composiciones plaguicidas | |
NZ533310A (en) | Benzimidazoles useful as protein kinase inhibitors | |
AR082888A1 (es) | Compuestos de piridina para la inhibicion de nampt | |
AR057979A1 (es) | PIRAZOLPIRIMIDINAS COMO INHIBIDORAS DE PROTEíNA QUINASA. COMPOSICIONES FARMACEUTICAS. | |
TW200800949A (en) | Macrocylic inhibitors of hepatitis C virus | |
AR076798A1 (es) | Pirazinilpirazoles y composiciones que comprenden dichos compuestos | |
PE20030062A1 (es) | Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas | |
MX2010000658A (es) | Derivados de pirimidina 934. | |
RU2008152065A (ru) | Новое производное имидазола со спироциклической структурой в боковой цепи | |
WO2007149448A3 (en) | Pyrazinones as cellular proliferation inhibitors | |
AR062965A1 (es) | Compuestos moduladores de receptores de glutamatometabotropicos mglur5, composiciones farmaceuticas que los contienen y usos terapeuticos en trastornos gastrointestinales, neurologicos y psiquiatricos agudos y cronicos | |
CY1107747T1 (el) | Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης | |
MX2009006650A (es) | Pirimidinas substituidas que contienen una porcion heteroarilamida o heteroarilfenilo. | |
EA200700758A1 (ru) | Новые производные бис-азаиндолов, их получение и фармацевтическое применение в качестве ингибиторов киназ | |
CY1110145T1 (el) | Αλκυλο-υποκατεστημενες ινδολοκινοξαλινες | |
PE20201068A1 (es) | Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos | |
HRP20050082A2 (en) | 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors | |
AR045791A1 (es) | Derivados de triazol sustituidos como antagonistas de oxitocina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |